Novel Pyridines Restore Nerve Conduction
Solution Overview
Problem
Current treatments for spinal cord injuries, such as those using 4-aminopyridine, often result in significant side effects and limited effectiveness in restoring nerve impulse conduction, with only about 30% of patients experiencing clinically meaningful recoveries, and require complex surgical procedures for intrathecal administration.
Innovation Solution
Development of novel substituted pyridines that act as potassium channel blockers, capable of restoring nerve impulse conduction through nerve tissue lesions with longer-lasting effects at lower concentrations, reducing the deleterious effects of traumatic CNS tissue injury, and administered in a more straightforward manner.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 4-aminopyridine is used to restore nerve impulse conduction, then nerve function recovery is achieved, but significant side effects occur and only about 30% of patients experience clinically meaningful recoveries
Solution Approach 1:
The patent modifies the chemical structure of 4-aminopyridine by substituting the amino group with various functional groups (carboxylic acid, ester, amide, nitrile, etc.) to create analogs with improved pharmacological profiles. These structural parameter changes aim to maintain potassium channel blocking activity while reducing unwanted side effects and improving therapeutic efficacy in restoring nerve impulse conduction.
Solution Approach 2:
The patent develops composite pharmaceutical formulations containing the novel pyridine compounds combined with other therapeutic agents or delivery systems. This composite approach seeks to enhance the therapeutic effect on nerve tissue while mitigating the harmful side effects associated with 4-aminopyridine through synergistic or antagonistic interactions in the formulation.
2Reliability
If 4-aminopyridine is administered to restore nerve impulse conduction, then some functional recovery is achieved, but the duration of action is limited and requires repeated dosing
Solution Approach 1:
The patent employs prodrug formulations where the active pyridine compound is delivered in a modified form that provides sustained release. The prodrug undergoes gradual conversion to the active form in vivo, extending the duration of therapeutic action and maintaining effective concentrations for longer periods without requiring frequent re-dosing.
Solution Approach 2:
The patent utilizes long-acting formulations and sustained-release delivery systems that pre-establish therapeutic drug levels in the target tissue. This preliminary action ensures that effective concentrations are maintained over extended periods, reducing the frequency of administration needed to achieve and maintain nerve impulse conduction restoration.
3Reliability
If intrathecal administration is used to deliver 4-aminopyridine, then direct delivery to the spinal cord is achieved, but complex surgical procedures are required
Solution Approach 1:
The patent replaces the mechanical surgical approach of intrathecal catheter implantation with non-invasive or minimally invasive delivery methods. This includes oral administration, transdermal patches, or intranasal delivery systems that utilize physiological absorption pathways to achieve adequate drug concentrations at the spinal cord without requiring surgical intervention.
Solution Approach 2:
The patent employs carrier molecules, absorption promoters, or delivery vehicles that act as intermediaries to facilitate drug transport across biological barriers. These intermediaries enable systemic administration to achieve targeted delivery to the spinal cord by enhancing permeability or directing transport through specific physiological pathways, avoiding the need for direct intrathecal injection.
4Reliability
If high concentrations of 4-aminopyridine are used to achieve therapeutic effect, then nerve impulse conduction is restored, but unwanted side effects increase
Solution Approach 1:
The patent develops formulations and delivery systems that concentrate the therapeutic effect locally at the site of nerve tissue injury while minimizing systemic exposure. This includes targeted delivery mechanisms, localized release systems, or compounds with enhanced tissue specificity that achieve effective concentrations at the injury site without requiring high systemic doses, thereby reducing side effects.
Solution Approach 2:
The patent exploits the selective vulnerability of demyelinated or injured nerve fibers to potassium channel blockers. By utilizing the altered electrophysiological properties of injured tissue, the novel pyridine compounds can achieve therapeutic effects at lower concentrations than required for healthy tissue, converting the pathological state into a therapeutic opportunity and reducing the need for high dosing that causes side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel pyridines demonstrate significant restoration of nerve impulse conduction through damaged spinal cord tissue with reduced side effects, achieving longer-lasting effects at lower concentrations compared to 4-aminopyridine, as evidenced by SSEP testing, and can be safely delivered in a single dosage form.
Implementation Method 1
novel substituted pyridines that act as potassium channel blockers, capable of restoring nerve impulse conduction through nerve tissue lesions
Data Source
AI summary
The invention provides novel pyridines, pharmaceutical compositions comprising such pyridines, and the use of such compositions in treating injured mammalian nerve tissue, including but not limited to an injured spinal cord, in one embodiment, the compounds, compositions, and methods of the instant invention treat a mammalian nerve tissue injury by restoring action potential or nerve impulse conduction through a nerve tissue lesion. Significantly, in vivo application of compounds of the instant invention established, on the basis of SSEP testing, that the compounds provide longer lasting effects at lower concentrations than comparable treatment with the known agent 4-aminopyridine (4 AP).